Abstract
Pirfenidone (Esbriet®), a synthetic pyridine compound with antifibrotic, anti-inflammatory and antioxidant properties that inhibit the progression of tissue fibrosis, is indicated for the treatment of idiopathic pulmonary fibrosis (IPF). In clinical trials in patients with mild to moderate IPF, oral pirfenidone generally provided a reduced rate of decline in forced vital capacity, while prolonging progression-free survival and reducing the risk of IPF-related and all-cause mortality. Pirfenidone has a manageable tolerability profile; however, gastrointestinal and skin-related events are common. Data from longer-term and real-world studies of pirfenidone use in patients with IPF are consistent with those in clinical trials.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
